New ACS Platform Streamlines Drug Discovery by Screening Crude Reaction Mixtures Directly
- A direct-to-biology (D2B) platform synthesizes candidate compounds at small scale and evaluates the crude reaction mixtures directly in biological assays, bypassing conventional purification.
- The approach couples miniaturized, automation-compatible chemistry with rapid biological readout to shorten the design-make-test cycle typical of early hit-finding and library exploration.
- Positioned within a broader wave of D2B methodology in medicinal chemistry, applicable to accelerating hit identification across diverse chemotypes.
💡 Points
Skipping purification is the real win—cuts days off the DMT cycle when you're triaging hundreds of analogs. But I want hard numbers on false-positive rates from residual catalyst/byproducts before trusting crude-mixture hits blind; great for rapid SAR triage, not for anything feeding a confirmatory dose-response.